The company's low P/S ratio is due to its recent three-year growth being lower than the wider industry forecast. Shareholders accept this as they anticipate no future revenue surprises. Unless medium-term conditions improve, they will continue to form a barrier for the share price.

Despite a substantial share price drop, an increase in EPS and revenue may provide an investment opportunity. However, the consistent drop indicates weak market sentiment, possibly due to over-hype or current conditions affecting biotech stocks.